JP2023554467A5 - - Google Patents

Info

Publication number
JP2023554467A5
JP2023554467A5 JP2023537253A JP2023537253A JP2023554467A5 JP 2023554467 A5 JP2023554467 A5 JP 2023554467A5 JP 2023537253 A JP2023537253 A JP 2023537253A JP 2023537253 A JP2023537253 A JP 2023537253A JP 2023554467 A5 JP2023554467 A5 JP 2023554467A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
acid sequence
cdr1
cdr2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023537253A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023554467A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/CN2021/138845 external-priority patent/WO2022127871A1/en
Publication of JP2023554467A publication Critical patent/JP2023554467A/ja
Publication of JP2023554467A5 publication Critical patent/JP2023554467A5/ja
Pending legal-status Critical Current

Links

JP2023537253A 2020-12-17 2021-12-16 Gucy2c結合分子及びその使用 Pending JP2023554467A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2020/137164 2020-12-17
CN2020137164 2020-12-17
PCT/CN2021/138845 WO2022127871A1 (en) 2020-12-17 2021-12-16 Gucy2c binding molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2023554467A JP2023554467A (ja) 2023-12-27
JP2023554467A5 true JP2023554467A5 (cg-RX-API-DMAC7.html) 2025-01-08

Family

ID=82060074

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023537253A Pending JP2023554467A (ja) 2020-12-17 2021-12-16 Gucy2c結合分子及びその使用

Country Status (15)

Country Link
US (1) US20240059794A1 (cg-RX-API-DMAC7.html)
EP (1) EP4263615A4 (cg-RX-API-DMAC7.html)
JP (1) JP2023554467A (cg-RX-API-DMAC7.html)
KR (1) KR20230131183A (cg-RX-API-DMAC7.html)
CN (2) CN118146381A (cg-RX-API-DMAC7.html)
AU (1) AU2021404641A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023011658A2 (cg-RX-API-DMAC7.html)
CA (1) CA3205007A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023001665A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023009279A2 (cg-RX-API-DMAC7.html)
CR (1) CR20230245A (cg-RX-API-DMAC7.html)
EC (1) ECSP23053774A (cg-RX-API-DMAC7.html)
IL (1) IL303610A (cg-RX-API-DMAC7.html)
MX (1) MX2023006969A (cg-RX-API-DMAC7.html)
WO (1) WO2022127871A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024027815A1 (zh) * 2022-08-05 2024-02-08 江苏恒瑞医药股份有限公司 特异性结合gucy2c和cd3的抗原结合分子及其医药用途
CN115894697B (zh) * 2022-12-09 2023-08-29 华道(上海)生物医药有限公司 一种抗鸟苷酸环化酶2c的纳米抗体及其应用
WO2026086785A1 (en) * 2024-10-21 2026-04-30 Shenzhen Wondercel Biotechnology Limited Eukaryotic cells expressing exogenous inosine monophosphate dehydrogenase comprising chimeric antigen receptor binding to gucy2c

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009080764A2 (en) * 2007-12-20 2009-07-02 Abylnx N.V. Oral or nasal administration of compounds comprising amino acid sequences
US9156915B2 (en) * 2012-04-26 2015-10-13 Thomas Jefferson University Anti-GCC antibody molecules
HRP20191690T1 (hr) * 2012-04-27 2019-12-27 Millennium Pharmaceuticals, Inc. Molekule anti-gcc antitijela i njihova uporaba u ispitivanju osjetljivosti na gcc-ciljanu terapiju
CN105384825B (zh) * 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2019014891A1 (zh) * 2017-07-20 2019-01-24 深圳普瑞金生物药业有限公司 一种用于治疗肿瘤的egfr单域抗体cart及其应用
BR112020013244A2 (pt) * 2018-01-04 2020-12-01 Shanghai Lumosa Therapeutics Co., Ltd. proteínas de fusão de anticorpo citosina-desaminase de domínio único
US11525010B2 (en) * 2018-05-23 2022-12-13 Pfizer Inc. Antibodies specific for GUCY2c and uses thereof
US11981920B2 (en) * 2018-12-04 2024-05-14 Innovative Cellular Therapeutics Holdings, Ltd. Modified cell with enhanced migration capability

Similar Documents

Publication Publication Date Title
JP2021087455A5 (cg-RX-API-DMAC7.html)
JP2025028239A5 (cg-RX-API-DMAC7.html)
JP2021094037A5 (cg-RX-API-DMAC7.html)
JP2025065142A5 (cg-RX-API-DMAC7.html)
JP2024125370A (ja) クローディン18.2結合部分およびその利用
JP2022542543A5 (cg-RX-API-DMAC7.html)
HRP20241057T1 (hr) Kimerni antigenski receptori na osnovu jedno-domenskih antitijela i načini njihove uporabe
TWI874613B (zh) 微型導引和導航控制(miniGNC)類抗體蛋白及其製造和使用方法
CA3086653A1 (en) Tumor necrosis factor (tnf) receptor superfamily (tnfrsf) receptor-activating antibody fusion proteins with fcyr-independent agonistic activity (tnfrsf receptor-activating antibody fusion proteins with fcyr-independ ent agonistic activity; traaffiaa)
JP2021526844A5 (cg-RX-API-DMAC7.html)
JP2023546766A5 (cg-RX-API-DMAC7.html)
JP2020511947A5 (cg-RX-API-DMAC7.html)
CN107921104A (zh) 结合cd137的抗体疗法
JP2016514457A5 (cg-RX-API-DMAC7.html)
JP2023546764A5 (cg-RX-API-DMAC7.html)
CA3210934A1 (en) Novel anti-cd24 antibodies
JP2018526981A5 (cg-RX-API-DMAC7.html)
JP2019524100A5 (cg-RX-API-DMAC7.html)
JP2020530777A (ja) 多重特異性抗体とその作製及び使用方法
CN116390953A (zh) 靶向人密蛋白18.2的抗体及其用途
JP2023543493A5 (cg-RX-API-DMAC7.html)
JP2023525778A5 (cg-RX-API-DMAC7.html)
JP2022513372A5 (cg-RX-API-DMAC7.html)
JP2023524811A5 (cg-RX-API-DMAC7.html)
JP2024504162A5 (cg-RX-API-DMAC7.html)